The optimal number of induction chemotherapy cycles in clinically lymph node-positive bladder cancer,BJU International

当前位置： X-MOL 学术 › BJU Int. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

The optimal number of induction chemotherapy cycles in clinically lymph node-positive bladder cancer
BJU International ( IF 4.5 ) Pub Date : 2024-03-12 , DOI: 10.1111/bju.16319
Markus von Deimling _{1,

2} , Laura S. Mertens ₃ , Marc Furrer _{4,

5} , Roger Li ₆ , Guus A.H. Tendijck ₃ , Jacob Taylor ₇ , Felice Crocetto ₈ , Moritz Maas _{9,

10} , Andrea Mari ₁₁ , Renate Pichler ₁₂ , Marco Moschini ₁₃ , Karl H. Tully ₁₄ , David D'Andrea ₁ , Ekaterina Laukhtina ₁ , Francesco Del Giudice ₁₅ , Gautier Marcq _{16,

17} , Maud Velev ₁₈ , Andrea Gallioli ₁₉ , Simone Albisinni _{20,

21} , Keiichiro Mori ₂₂ , Abhinav Khanna ₂₃ , Michael Rink ₂₄ , Margit Fisch ₂ , Andrea Minervini ₁₁ , Peter C. Black ₁₀ , Yair Lotan ₇ , Philippe E. Spiess ₆ , Bernhard Kiss ₄ , Shahrokh F. Shariat _{1,

7,

25,

26,

27} , Benjamin Pradere _{1,

28} ,

Affiliation

Department of Urology, Comprehensive Cancer Center Medical University of Vienna Vienna Austria
Department of Urology University Medical Center Hamburg‐Eppendorf Hamburg Germany
Department of Urology The Netherlands Cancer Institute Amsterdam The Netherlands
Department of Urology, University Hospital of Bern University of Bern Bern Switzerland
Department of Urology, Solothurner Spitäler AG Kantonsspital Olten and Bürgerspital Solothurn Switzerland
Department of Genitourinary Oncology H. Lee Moffitt Cancer Center and Research Institute Tampa FL USA
Department of Urology University of Texas Southwestern Dallas TX USA
Department of Neurosciences, Reproductive Sciences and Odontostomatology University of Naples "Federico II" Naples Italy
Department of Urology Eberhard Karls University Tübingen Tübingen Germany
Department of Urologic Sciences University of British Columbia Vancouver BC Canada
Unit of Oncologic Minimally‐Invasive Urology and Andrology, Department of Experimental and Clinical Medicine, Careggi Hospital University of Florence Florence Italy
Department of Urology, Comprehensive Cancer Center Innsbruck Medical University of Innsbruck Innsbruck Austria
Department of Urology, Urological Research Institute Vita‐Salute San Raffaele Milan Italy
Department of Urology and Neurourology, Marien Hospital Herne Ruhr‐University Bochum Herne Germany
Department of Maternal Infant and Urologic Sciences, Policlinico Umberto I Hospital “Sapienza” University of Rome Rome Italy
Department of Urology, CHU Lille Claude Huriez Hospital Lille France
CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020‐U1277 – CANTHER – Cancer Heterogeneity Plasticity and Resistance to Therapies University of Lille Lille France
Department of Cancer Medicine, Gustave Roussy Université Paris‐Saclay Villejuif France
Department of Urology, Fundació Puigvert Autonomous University of Barcelona Barcelona Spain
Urology Unit, Department of Surgical Sciences, Tor Vergata University Hospital University of Rome Tor Vergata Rome Italy
Service d'Urologie, Hôpital Erasme Université Libre de Bruxelles Bruxelles Belgium
Department of Urology The Jikei University School of Medicine Tokyo Japan
Department of Urology Mayo Clinic Rochester MN USA
Department of Urology Marienkrankenhaus Hamburg Germany
Karl Landsteiner Institute of Urology and Andrology Vienna Austria
Department of Urology Weill Cornell Medical College New York NY USA
Hourani Center for Applied Scientific Research Al‐Ahliyya Amman University Amman Jordan
Department of Urology Urosud, La Croix Du Sud Hospital Quint‐Fonsegrives France

To investigate the optimal number of induction chemotherapy cycles needed to achieve a pathological response in patients with clinically lymph node-positive (cN+) bladder cancer (BCa) who received three or four cycles of induction chemotherapy followed by consolidative radical cystectomy (RC) with pelvic lymph node dissection.

中文翻译：